- The share
- Press releases
- Financial calendar
- Financial reports and prospectus
- Financial presentations
- Corporate governance
- Analyst Coverage
Stock Exchange listing
XVIVO Perfusion is listed on Nasdaq Stockholm mid cap list. The share has been listed on Nasdaq Stockholm mid cap since November 28, 2016. The XVIVO Perfusion share was before that listed on Nasdaq First North since October 8, 2012.
Trading lot: 1 share
According to Euroclear Sweden’s official share register as of December 31, 2016, the total number of shareholders were 5 296. The top 10 largest shareholders held approximately 46.5 percent of the shares.
|Bure, AB Equity||4 891 483||20.7%|
|Eccenovo AB||1 450 000||6.1%|
|Thomas Olausson||1 100 000||4.7%|
|Handelsbanken Liv||1 029 445||4.4%|
|Försäkringsaktiebolaget, Avanza pension||582 299||2.5%|
|Nordnet Pensionsförsäkring AB||539 230||2.3%|
|Carl Westin Limited||420 840||1.8%|
|UBS Europe SE, Luxembourg branch||348 012||1.5%|
|Leif Bergvall||310 747||1.3%|
|Ingvar Andersson||300 000||1.3%|
|Top 10 largest shareholders, total||10 972 056||46.5%|
|Other shareholders||12 642 032||53.5%|
|Total||23 614 088||100%|
Allotment of acquisition cost XVIVO Perfusion decided by the Swedish Tax Agency.
In connection with Vitrolife’s distribution of the shares in Xvivo Perfusion AB, the Swedish Tax Agency has decided that 77% of the acquisition cost should be allotted to Vitrolife AB and 23% to Xvivo Perfusion AB.
Further information can be found on the Swedish Tax Agency’s website www.skatteverket.se